Trial reportNature medicine2025
Patritumab deruxtecan in HR
Abstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Trial watch: antibody-drug conjugates in cancer therapy.Oncoimmunology · 2026Review
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.The Journal of clinical investigation · 2026Review
- Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.Journal of hematology & oncology · 2026Review
- Pathophysiological and Molecular Features of DXd ADC-Related Interstitial Pneumonitis in Cynomolgus Monkeys.Cancer science · 2026Article
- The next generation of antibody-drug conjugates.Nature medicine · 2026Review
- Review
- Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice.Molecular cancer · 2026Review
- Antibody-drug conjugates in breast cancer: Progress and future directions.Cell reports. Medicine · 2026Review
- The Current Landscape of Metastatic Breast Cancer: A Pathology Guide on Emerging Biomarkers.Cancers · 2026Review
- Antibody-Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions.Biomolecules · 2026Review
- Roles of Her3 in carcinogenesis and advances in Her3-targeted cancer therapy.Discover oncology · 2026Review
- HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance.Journal of translational medicine · 2026Review
- Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Research Progress of HER2 in Cervical Carcinoma.Cancer management and research · 2026Review
- Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.NPJ precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Barbara PistilliDepartment of Medical Oncology, Gustave Roussy, Villejuif, France. barbara.pistilli@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-9184-7199
Fernanda Mosele *Department of Medical Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-7841-2900
Noemie Corcos *INSERM 1279, Gustave Roussy, Villejuif, France.
Livia PierottiIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.
Yoann PradatIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.
Loic Le BescondIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.
Magali Lacroix-TrikiIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-6641-8536
Ghada NachabehProjects and Promotion Division, Gustave Roussy, Villejuif, France.
Alexia AlfaroUMS AMMICa, CNRS UAR 3655, INSERM US23, Gustave Roussy, Villejuif, France.
Cyril CatelainUMS AMMICa, CNRS UAR 3655, INSERM US23, Gustave Roussy, Villejuif, France.
Bastien JobIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-2720-7664
Fathia Mami-ChouaibUMR1186, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-9685-6011
Severine BadelUMR1186, Gustave Roussy, Villejuif, France.
Françoise FaraceIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-8563-160X
Marianne OulhenIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.
Patricia KannoucheUMR9019-CNRS, Université Paris-Saclay, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-6050-3457
Diep T N TranIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-3982-4221
Nathalie DroinIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-6099-5324
Cecile VicierDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, France.
Jean Sebastien FrenelDepartment of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint Herblain, France.ORCID http://orcid.org/0000-0002-5273-0561
Veronique D'HondtDepartment of Medical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0001-5238-4032
Florence DalencDepartment of Medical Oncology, Oncopole Claudius Regaud, Toulouse, France.
Thomas BachelotDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-0866-9484
Agnes DucoulombierDepartment of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
Marc Antoine BenderraDepartment of Medical Oncology, Tenon Hospital, APHP, Paris, France.
Delphine LoiratDepartment of Medical Oncology, Curie Hospital, Paris, France.
Didier MayeurDepartment of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
Elise DelucheDepartment of Medical Oncology, Centre Hopital-Universitaire, Limoges, France.ORCID http://orcid.org/0000-0001-8474-3116
Jacqueline DeneuveDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.
Rasha Cheikh-HussinINSERM 1279, Gustave Roussy, Villejuif, France.
Pierre GuyaderOffice of Biostatistics and Epidemiology, Gustave Roussy, Oncostat INSERM U1018, Université Paris-Saclay, Ligue Contre le Cancer, Villejuif, France.ORCID http://orcid.org/0009-0009-5767-3912
Nicolas SignolleDepartment of Pathology, Gustave Roussy, Villejuif, France.
Karine GodefroyDepartment of Pathology, Gustave Roussy, Villejuif, France.
Hugues TalbotCentraleSupélec, Inria, Université Paris-Saclay, Gif-Sur-Yvette, France.ORCID http://orcid.org/0000-0002-2179-3498
Maria VakalopoulouIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.
Stergios ChristodoulidisIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-8773-1070
Elsa BernardIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.
Yves KoudouOffice of Biostatistics and Epidemiology, Gustave Roussy, Oncostat INSERM U1018, Université Paris-Saclay, Ligue Contre le Cancer, Villejuif, France.
Andrea SporchiaDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Fumitaka SutoDaiichi Sankyo Inc., Basking Ridge, NJ, USA.ORCID http://orcid.org/0009-0009-5649-2650
Lie LiDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
David W SternbergDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Stefan MichielsIHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-6963-2968
Fabrice AndréDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-5795-8357
Dalila SellamiDaiichi Sankyo Inc., Basking Ridge, NJ, USA.
Guillaume MontagnacINSERM 1279, Gustave Roussy, Villejuif, France.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates have shown impressive clinical outcomes, particularly in metastatic breast cancer, but biomarkers to predict response and resistance remain unidentified. Here we report the results of ICARUS-BREAST01, a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR
Indexed as
Antibodies, Monoclonal, HumanizedBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesAdultAgedBiomarkers, TumorEstrogen Receptor alphaFemaleHumansMiddle AgedReceptor, ErbB-3Receptors, EstrogenReceptors, ProgesteroneAntibodies, Monoclonal, HumanizedBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaImmunoconjugatesReceptor, ErbB-3Receptors, EstrogenReceptors, Progesterone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.